A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. (Cancer)

Authors :: Phillips, R.K.S.
Wallace, M.H.
Lynch, P.M.
Hawk, E.
Gordon, G.B.
Saunders, B.P.
Wakabayashi, N.
Shen, Y.
Zimmerman, S.
Godio, L.
Rodrigues-Bigas, M.
Su, L.K.
Sherman, J.
Kelloff, G.
Levin, B.
Steinbach, G.
Source :: Gut. June 2002, Vol. 50 Issue 6, p857, 4 p.
Publication Year :: 2002
Abstract: Background: Non-selective cyclooxygenase (COX) inhibitors (non-steroidal anti-inflammatory drugs) inhibit large bowel carcinogenesis in patients with familial adenomatous polyposis (FAP). Their role in the duodenum of these patients is less certain. [...]

Subjects :: Drug therapy
Prevention
Physiological aspects
Familial polyposis -- Drug therapy -- Prevention
Celecoxib -- Physiological aspects
Carcinogenesis -- Prevention -- Drug therapy
Polyposis, Familial -- Drug therapy -- Prevention

Tools